Determining ICU EEG periodic patterns and why it matters.

"Declarations Conflicts of interestDr. Gélisse received support for teaching programs from UCB, Eisai and royalties for publishing from John Libbey Eurotext. Dr. Tatum has received a stipend from Elsevier as Editor-in-Chief of Epilepsy Behavior Report. He serves on the editorial board for the Journal of Clinical Neurophysiology and Epilepsy Behavior Reports. He is a consultant for BioSerenity/DigiTrace Care Services, Inc., Neurelis, Natus, and LivaNova and holds patents or patents pending for intraoperative monitoring devices (#62527896; #62770362). He receives royalties for publishing from Demos Publishers Inc., Springer Publishing, Wiley, and MedLink and honoraria for speaking engagements from the American Academy of Neurology, American Epilepsy Society, and American Clinical Neurophysiology Society (ACNS). He has research support from Mayo Clinic, Martin Family Foundation, Eisai Inc., LivaNova, Xenon Pharma, Cerevel Therapeutics, and McElvey Foundation. Dr. Crespel received support for teaching programs from UCB, Eisai and royalties for publishing from John Libbey Eurotext. She was an advisory board member for Eisai-France. Dr. Jallon reports no conflicts of interest. Dr. Kaplan has been on the board of the American Board of Clinical Neurophysiology, the American Clinical Neurophysiology Society, consulted for Ceribell and lectured on EEG. Conflicts of interest Dr. Gélisse received support for teaching programs from UCB, Eisai and royalties for publishing from John Libbey Eurotext. Dr. Tatum has received a stipend from Elsevier as Editor-in-Chief of Epilepsy Behavior Report. He serves on the editorial board for the Journal of Clinical Neurophysiology and Epilepsy Behavior Reports. He is a consultant for BioSerenity/DigiTrace Care Services, Inc., Neurelis, Natus, and LivaNova and holds patents or patents pending for intraoperative monitoring devices (#62527896; #62770362). He receives royalties for publishing from Demos Publishers Inc., Springer Publishing, Wiley, and MedLink and honoraria for speaking engagements from the American Academy of Neurology, American Epilepsy Society, and American Clinical Neurophysiology Society (ACNS). He has research support from Mayo Clinic, Martin Family Foundation, Eisai Inc., LivaNova, Xenon Pharma, Cerevel Therapeutics, and McElvey Foundation. Dr. Crespel received support for teaching programs from UCB, Eisai and royalties for publishing from John Libbey Eurotext. She was an advisory board member for Eisai-France. Dr. Jallon reports no conflicts of interest. Dr. Kaplan has been on the board of the American Board of Clinical Neurophysiology, the American Clinical Neurophysiology Society, consulted for Ceribell and lectured on EEG."

"Declarations: Conflicts of interestDr. Gélisse received support for teaching programs from UCB, Eisai and royalties for publishing from John Libbey Eurotext. Dr. Tatum has received a stipend from Elsevier as Editor-in-Chief of Epilepsy Behavior Report. He serves on the editorial board for the Journal of Clinical Neurophysiology and Epilepsy Behavior Reports. He is a consultant for BioSerenity/DigiTrace Care Services, Inc., Neurelis, Natus, and LivaNova and holds patents or patents pending for intraoperative monitoring devices (#62527896; #62770362). He receives royalties for publishing from Demos Publishers Inc., Springer Publishing, Wiley, and MedLink and honoraria for speaking engagements from the American Academy of Neurology, American Epilepsy Society, and American Clinical Neurophysiology Society (ACNS). He has research support from Mayo Clinic, Martin Family Foundation, Eisai Inc., LivaNova, Xenon Pharma, Cerevel Therapeutics, and McElvey Foundation. Dr. Crespel received support for teaching programs from UCB, Eisai and royalties for publishing from John Libbey Eurotext. She was an advisory board member for Eisai-France. Dr. Jallon reports no conflicts of interest. Dr. Kaplan has been on the board of the American Board of Clinical Neurophysiology, the American Clinical Neurophysiology Society, consulted for Ceribell and lectured on EEG. Conflicts of interest: Dr. Gélisse received support for teaching programs from UCB, Eisai and royalties for publishing from John Libbey Eurotext. Dr. Tatum has received a stipend from Elsevier as Editor-in-Chief of Epilepsy Behavior Report. He serves on the editorial board for the Journal of Clinical Neurophysiology and Epilepsy Behavior Reports. He is a consultant for BioSerenity/DigiTrace Care Services, Inc., Neurelis, Natus, and LivaNova and holds patents or patents pending for intraoperative monitoring devices (#62527896; #62770362). He receives royalties for publishing from Demos Publishers Inc., Springer Publishing, Wiley, and MedLink and honoraria for speaking engagements from the American Academy of Neurology, American Epilepsy Society, and American Clinical Neurophysiology Society (ACNS). He has research support from Mayo Clinic, Martin Family Foundation, Eisai Inc., LivaNova, Xenon Pharma, Cerevel Therapeutics, and McElvey Foundation. Dr. Crespel received support for teaching programs from UCB, Eisai and royalties for publishing from John Libbey Eurotext. She was an advisory board member for Eisai-France. Dr. Jallon reports no conflicts of interest. Dr. Kaplan has been on the board of the American Board of Clinical Neurophysiology, the American Clinical Neurophysiology Society, consulted for Ceribell and lectured on EEG."